Diese Erfindung befasst sich mit der Bereitstellung von Arzneiformen, die es ermöglichen, den Wirkstoff Betahistin, der üblicherweise wenigstens zweimal oder mehrmals täglich eingenommen werden muss, im Wege einer einmal täglichen Gabe wirksam darzureichen. Dies wird erfindungsgemäss erreicht durch Bereitstellung einer Arzneiform umfassend einen Kern, eine Zwischenschicht, die auf der Oberfläche des Kerns angeordnet ist, und einen Mantel, der auf der dem Kern gegenüberliegenden Seite der Zwische...

The present invention provides a controlled release dosage form comprising a mixture of betahistine or its pharmaceutically acceptable salt complexed with ion exchange resin with one or more gel forming polymer. Further, in preferred aspect, the present invention provides a controlled release solid dosage form comprising " a controlled release composition comprising betahistine or its pharmaceutically acceptable salt, one or more gel forming polymers and pharmaceutically acceptable excipients

This invention is related to pharmaceutical combination of betahistine or pharmaceutically acceptable salts thereof and trimetazidine or pharmaceutically acceptable salts thereof.

This invention is related to pharmaceutical combination of betahistine or pharmaceutically acceptable salts thereof and trimetazidine or pharmaceutically acceptable salts thereof.

Provided is the se of betahistine in the manufacture of a medicament for preventing or treating a Eustachian tube dysfunction, wherein the medicament is formulated for topical application to a Eustachian tube of a subject in need thereof. The medicament can be administered by nasopharynx by a nasal spray.

Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount of a histamine type 3 (H3) receptor antagonist, such as betahistine or its pharmaceutically acceptabl...

The present invention relates to new water dispersible pharmaceutical formulations comprising betahistine as the active agent.

Methods, compositions and drug combinations utilizing betahistine, a pharmaceutically acceptable salt there of or a metabolite thereof, for reducing somnolence in a subject treated with a somnolence-inducing drug are disclosed.